Literature DB >> 19558782

Autologous bone-marrow mononuclear cell transplantation after acute myocardial infarction: comparison of two delivery techniques.

Suzana A Silva1, André L S Sousa, Andrea F Haddad, Jader C Azevedo, Vinicio E Soares, Cíntia M Peixoto, Ana J S Soares, Aurora F C Issa, Luis Renato V Felipe, Rodrigo V C Branco, João A Addad, Rodrigo C Moreira, Fabio A A Tuche, Cláudio T Mesquita, Cristina C O Drumond, Amarino O Junior, Carlos E Rochitte, José H M Luz, Arnaldo Rabischoffisky, Fernanda B Nogueira, Rosana B C Vieira, Hamilton S Junior, Radovan Borojevic, Hans F R Dohmann.   

Abstract

The objective of this study was to investigate safety and feasibility of autologous bone marrow mononuclear cells (BMMNC) transplantation in ST elevation myocardial infarction (STEMI), comparing anterograde intracoronary artery (ICA) delivery with retrograde intracoronary vein (ICV) approach. An open labeled, randomized controlled trial of 30 patients admitted with STEMI was used. Patients were enrolled if they 1) were successfully reperfused within 24 h from symptoms onset and 2) had infarct size larger than 10% of the left ventricle (LV). One hundred million BMMNC were injected in the infarct-related artery (intra-arterial group) or vein (intravenous group), 1% of which was labeled with Tc(99m)-hexamethylpropylenamineoxime. Cell distribution was evaluated 4 and 24 h after injection. Baseline MRI was performed in order to evaluate microbstruction pattern. Baseline radionuclide ventriculography was performed before cell transfer and after 3 and 6 months. All the treated patients were submitted to repeat coronary angiography after 3 months. Thirty patients (57 +/- 11 years, 70% males) were randomly assigned to ICA (n = 14), ICV (n = 10), or control (n = 6) groups. No serious adverse events related to the procedure were observed. Early and late retention of radiolabeled cells was higher in the ICA than in the ICV group, independently of microcirculation obstruction. An increase of EF was observed in the ICA group (p = 0.02) compared to baseline. Injection procedures through anterograde and retrograde approaches seem to be feasible and safe. BMMNC retention by damaged heart tissue was apparently higher when the anterograde approach was used. Further studies are required to confirm these initial data.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558782     DOI: 10.3727/096368909788534951

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  28 in total

Review 1.  SPECT and PET to optimize cardiac stem cell therapy.

Authors:  Angel T Chan; M Roselle Abraham
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

Review 2.  Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction.

Authors:  Jay H Traverse
Journal:  J Cardiovasc Transl Res       Date:  2011-11-17       Impact factor: 4.132

3.  Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly luciferase.

Authors:  Sophie E Boddington; Tobias D Henning; Priyanka Jha; Christopher R Schlieve; Lydia Mandrussow; David DeNardo; Harold S Bernstein; Carissa Ritner; Daniel Golovko; Ying Lu; Shoujun Zhao; Heike E Daldrup-Link
Journal:  Cell Transplant       Date:  2010       Impact factor: 4.064

Review 4.  Imaging cardiac stem cell transplantation using radionuclide labeling techniques: clinical applications and future directions.

Authors:  Luka Lezaic; François Haddad; Bojan Vrtovec; Joseph C Wu
Journal:  Methodist Debakey Cardiovasc J       Date:  2013 Oct-Dec

Review 5.  Cell therapy for the treatment of coronary heart disease: a critical appraisal.

Authors:  Kai C Wollert; Helmut Drexler
Journal:  Nat Rev Cardiol       Date:  2010-02-23       Impact factor: 32.419

6.  Multimodality molecular imaging in cardiac regenerative therapy.

Authors:  Davis Vo; Patricia K Nguyen
Journal:  J Nucl Cardiol       Date:  2017-02-09       Impact factor: 5.952

7.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

Review 8.  Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Authors:  Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circulation       Date:  2012-06-22       Impact factor: 29.690

Review 9.  Emerging roles for integrated imaging modalities in cardiovascular cell-based therapeutics: a clinical perspective.

Authors:  Peter J Psaltis; Robert D Simari; Martin Rodriguez-Porcel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-08       Impact factor: 9.236

10.  MRI-3D ultrasound-X-ray image fusion with electromagnetic tracking for transendocardial therapeutic injections: in-vitro validation and in-vivo feasibility.

Authors:  Charles R Hatt; Ameet K Jain; Vijay Parthasarathy; Andrew Lang; Amish N Raval
Journal:  Comput Med Imaging Graph       Date:  2013-04-03       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.